KRAS is usually mutated in PC, and the inactivation mutations of tumor suppressor genes such as CDKN2A/p16, TP53, and SMAD4 act synergistically with KRAS mutations to promote the occurrence and development of PC [22]. The gene discussed is CDKN2A; the disease is pachyonychia congenita.